SillaJen is a privately-held biotechnology company focused on engineering and developing best-in-class oncolytic virus immunotherapeutics. A global leader in oncolytic immunotherapeutics Targeting, Attacking and Eradicating Cancers
Employees: 11-50
Total raised: $12M
Founded date: 2006
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.03.2016 | - | $12M | Medivate P... |
Mentions in press and media 6
| Date | Title | Description | Source |
| 22.04.2024 | OSR Holdings and SillaJen have entered into a Memorandum of ... | SEOUL, South Korea, April 22, 2024 /PRNewswire/ -- OSR Holdings, a global healthcare holding company... | en.prnasia... |
| 19.12.2022 | Basilea announces transition milestone for oncology asset BA... | /EIN News/ -- Basel/Allschwil, Switzerland, December 19, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN)... | einpresswi... |
| 19.12.2022 | Basilea announces transition milestone for oncology asset BA... | - | globenewsw... |
| 31.05.2021 | SILLAJEN, INC. SillaJen, Inc. announced that it expects to ... | SillaJen, Inc. (KOSDAQ:A215600) announced a private placement of 18,750,000 shares at an issue price... | marketscre... |
| 22.03.2016 | S Korean biotech firm Sillajen raises $12m from Medivate Par... | Premium Sillajen, a South Korea-based oncolytic immunotherapeutic startup, has raised $12 million fu... | dealstreet... |
| 21.03.2016 | Sillajen Raises $12M in Funding | Sillajen, a Seoul, South Korea-based global oncolytic immunotherapeutic company, raised $12m in fund... | finsmes.co... |